全文获取类型
收费全文 | 6095篇 |
免费 | 330篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 123篇 |
妇产科学 | 87篇 |
基础医学 | 609篇 |
口腔科学 | 102篇 |
临床医学 | 365篇 |
内科学 | 1883篇 |
皮肤病学 | 59篇 |
神经病学 | 645篇 |
特种医学 | 167篇 |
外科学 | 758篇 |
综合类 | 40篇 |
一般理论 | 5篇 |
预防医学 | 392篇 |
眼科学 | 235篇 |
药学 | 411篇 |
1篇 | |
中国医学 | 16篇 |
肿瘤学 | 494篇 |
出版年
2023年 | 46篇 |
2022年 | 39篇 |
2021年 | 187篇 |
2020年 | 104篇 |
2019年 | 184篇 |
2018年 | 201篇 |
2017年 | 159篇 |
2016年 | 157篇 |
2015年 | 168篇 |
2014年 | 213篇 |
2013年 | 337篇 |
2012年 | 485篇 |
2011年 | 467篇 |
2010年 | 278篇 |
2009年 | 246篇 |
2008年 | 424篇 |
2007年 | 437篇 |
2006年 | 429篇 |
2005年 | 372篇 |
2004年 | 277篇 |
2003年 | 301篇 |
2002年 | 264篇 |
2001年 | 76篇 |
2000年 | 52篇 |
1999年 | 43篇 |
1998年 | 48篇 |
1997年 | 30篇 |
1996年 | 26篇 |
1995年 | 28篇 |
1994年 | 24篇 |
1993年 | 15篇 |
1992年 | 38篇 |
1991年 | 30篇 |
1990年 | 22篇 |
1989年 | 30篇 |
1988年 | 26篇 |
1987年 | 23篇 |
1986年 | 17篇 |
1985年 | 14篇 |
1984年 | 12篇 |
1983年 | 9篇 |
1982年 | 18篇 |
1981年 | 13篇 |
1980年 | 9篇 |
1979年 | 7篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1975年 | 6篇 |
1974年 | 7篇 |
排序方式: 共有6455条查询结果,搜索用时 218 毫秒
1.
2.
Moisés Rodríguez-Mañero Estrella López-Pardo Alberto Cordero-Fort Jose Luis Martínez-Sande Carlos Peña-Gil José Novo Platas Javier García-Seara Pilar Mazón Alfonso Varela-Román Jose María García-Acuña José Ramón González-Juanatey 《Revista portuguesa de cardiologia》2019,38(1):21-29
Introduction
Today's healthcare policies rely heavily on data that has been gathered from multiple small studies in intrinsically varied populations. We sought to describe the prevalence, comorbidities and outcomes of atrial fibrillation (AF) in the population of a specific region where all healthcare centers have implemented a common information technology (IT) structure.Methods
The total number of inhabitants was obtained from the healthcare area's IT system. Information pertaining to AF was derived from various datasets in the data warehouse of the Galician regional health service.Results
In the healthcare area of Santiago de Compostela (n=383 000), the diagnosis of AF was coded in 7990 (2.08%) individuals in 2013. Mean age was 76.83±10.5 years, mean CHA2DS2-VASc score was 3.5, 4056 (50.8%) were female and 72.6% were receiving oral anticoagulants. Up until December 31, 2015, 1361 patients died from all causes (17%), 478 (6%) of them in-hospital, with 30 deaths secondary to intracranial bleeding (0.4%) and 125 to stroke (1.6%). On multivariate analysis, age, gender, heart failure, diabetes, previous thromboembolic events and dementia were independently associated with all-cause mortality. Similarly, age, gender and previous thromboembolic events were associated with future thromboembolic events. Oral anticoagulation was found to be protective against mortality and thromboembolic events.Conclusions
In this study, we report for the first time the true prevalence of diagnosed AF and its clinical characteristics, treatment and prognosis in a Spanish healthcare area, based on the systematic integration of data available from a universally adopted health IT system within the region. 相似文献3.
Licia Iaccarino Tiziana Ottone Valentina Alfonso Laura Cicconi Mariadomenica Divona Serena Lavorgna Serena Travaglini Aleandra Ferrantini Giulia Falconi Constance Baer Monica Usai Fabio Forghieri Adriano Venditti Maria Ilaria Del Principe William Arcese Maria Teresa Voso Torsten Haferlach Francesco Lo-Coco 《American journal of hematology》2019,94(10):1091-1097
Despite the high probability of cure of patients with acute promyelocytic leukemia (APL), mechanisms of relapse are still largely unclear. Mutational profiling at diagnosis and/or relapse may help to identify APL patients needing frequent molecular monitoring and early treatment intervention. Using an NGS approach including a 31 myeloid gene-panel, we tested BM samples of 44 APLs at the time of diagnosis, and of 31 at relapse. Mutations in PML and RARA genes were studied using a customized-NGS-RNA panel. Patients relapsing after ATRA-chemotherapy rarely had additional mutations (P = .009). In patients relapsing after ATRA/ATO, the PML gene was a preferential mutation target. We then evaluated the predictive value of mutations at APL diagnosis. A median of two mutations was detectable in 9/11 patients who later relapsed, vs one mutation in 21/33 patients who remained in CCR (P = .0032). This corresponded to a significantly lower risk of relapse in patients with one or less mutations (HR 0.046; 95% CI 0.011-0.197; P < .0001). NGS-analysis at the time of APL diagnosis may inform treatment decisions, including alternative treatments for cases with an unfavorable mutation profile. 相似文献
4.
José M. de la Torre Hernández Salvatore Brugaletta Joan A. Gómez Hospital José A. Baz Armando Pérez de Prado Ramón López Palop Belen Cid Tamara García Camarero Alejandro Diego Hipólito Gutiérrez José A. Fernández Diaz Juan Sanchis Fernando Alfonso Roberto Blanco Javier Botas Javier Navarro Cuartero José Moreu Francisco Bosa Antonio J. Domínguez 《Revista espa?ola de cardiología》2019,72(12):1005-1011
Background and objectivesPatients older than 75 years with ST-segment elevation myocardial infarction undergoing primary angioplasty in cardiogenic shock have high mortality. Identification of preprocedural predictors of short- and long-term mortality could be useful to guide decision-making and further interventions.MethodsWe analyzed a nationwide registry of primary angioplasty in the elderly (ESTROFA MI + 75) comprising 3576 patients. The characteristics and outcomes of the subgroup of patients in cardiogenic shock were analyzed to identify associated factors and prognostic predictors in order to derive a baseline risk prediction score for 1-year mortality. The score was validated in an independent cohort.ResultsA total of 332 patients were included. Baseline independent predictors of mortality were anterior myocardial infarction (HR 2.8, 95%CI, 1.4-6.0; P = .005), ejection fraction < 40% (HR 2.3, 95%CI, 1.14-4.50; P = .018), and time from symptom onset to angioplasty > 6 hours (HR 3.2, 95%CI, 1.6-7.5; P = .001). A score was designed that included these predictive factors (score “6-ANT-40”). Survival at 1 year was 54.5% for patients with score 0, 32.3% for score 1, 27.4% for score 2 and 17% for score 3 (P = .004, c-statistic 0.70). The score was validated in an independent cohort of 124 patients, showing 1-year survival rates of 64.5%, 40.0%, 28.9%, and 22.2%, respectively (P = .008, c-statistic 0.68).ConclusionsA preprocedural score based on 3 simple clinical variables (anterior location, ejection fraction < 40%, and delay time > 6 hours) may be used to estimate survival after primary angioplasty in elderly patients with cardiogenic shock and to guide preinterventional decision-making. 相似文献
5.
Maria Gonzalez-Cao Cristina Carrera Juan Francisco Rodriguez Moreno Pedro Rodríguez-Jiménez Mónica Antoñanzas Basa Rosa Feltes Ochoa Teresa Puertolas Eva Muñoz-Couselo José Luis Manzano Ivan Marquez-Rodas Juan Martín-Liberal Ainara Soria Pilar Lopez Criado Almudena Garcia-Castaño Aram Boada Pablo Ayala de Miguel Susana Puig Guillermo Crespo Alfonso Berrocal 《Journal of the American Academy of Dermatology》2021,84(5):1412-1415
6.
Green Cathrin D. Dvorsky Melissa R. Langberg Joshua M. Jones Heather A. Floyd Alfonso L. 《School mental health》2020,12(3):580-594
School Mental Health - Adolescents with Attention-deficit/hyperactivity disorder (ADHD) experience significant impairment in functioning. There are multiple clinic-based interventions that address... 相似文献
7.
8.
9.
Salvatore Giacomo Morano Roberto Latagliata Corrado Girmenia Fulvio Massaro Paola Berneschi Alfonso Guerriero Massimo Giampaoletti Arianna Sammarco Giorgia Annechini Angelo Fama Alice Di Rocco Antonio Chistolini Alessandra Micozzi Matteo Molica Walter Barberi Clara Minotti Gregorio Antonio Brunetti Massimo Breccia Claudio Cartoni Saveria Capria Giovanni Rosa Giuliana Alimena Robin Foà 《Supportive care in cancer》2015,23(11):3289-3295
10.
Giammaria Fiorentini Camillo Aliberti Donatella Sarti Paolo Coschiera Massimo Tilli Luca Mulazzani Paolo Giordani Francesco Graziano Alfonso Marqués Gonzalez Raul García Marcos Fernando Gómez Mugnoz Maurizio Cantore Stefano Ricci Vincenzo Catalano Andrea Mambrini 《World journal of gastrointestinal oncology》2015,7(6):47-54
AIM: To investigate efficacy and safety of second-line treatment with irinotecan-loaded drug-eluting beads (DEBIRI) and cetuximab (DEBIRITUX) of unresectable colorectal liver metastases.METHODS: Patients with the following characteristics were included in the study: unresectable hepatic metastases from colorectal carcinoma (CRC-LM), progression after first line chemotherapy (any type of chemotherapeutic drug and combination was allowed), second line treatment (mandatory), which included for each patient (unregarding the KRas status) two cycles of DEBIRI (using 100-300 μm beads loaded with irinotecan at a total dose 200 mg) followed by 12 cycles of cetuximab that was administered weekly at a first dose of 400 mg/m2 and then 250 mg/m2; good performance status (0-2) and liver functionality (alanine aminotransferase and gamma-glutamyl transferase not exceeding three times the upper limit of normal, total bilirubin not exceeding 2.5 mg/mL). Data were collected retrospectively and included: tumor response (evaluated monthly for 6 mo then every 3 mo), overall response rate (ORR), KRas status, type and intensity of adverse events (G according to the Common Terminology Criteria for Adverse Events v3.0, CTCAE), overall survival (OS) and progression free survival (PFS).RESULTS: Forty consecutive cases of CRC hepatic metastases were included in the study. Median duration of DEBIRITUX was 4.4 mo (range, 4.0-6.5). Sixteen patients (40%) received the planned 2 cycles of DEBIRI and an average of 10 cetuximab cycles. ORR of the whole sample was 50%, in particular 4 patients were complete responders (10%) and 16 (40%) partial responders. The most observed side effects (G2) were: post-embolization syndrome (30%), diarrhea (25%), skin rushes (38%) and asthenia (35%). The retrospective evaluation of KRas status (24 wild type, 16 mutated) showed that the group of patients with wild type KRas had ORR significantly higher than mutant KRas. Median follow-up was 29 mo (8-48 range); median PFS was 9.8 mo and OS was 20.4 mo. Future randomized trials are required in this setting to establish a role for DEBIRITUX compared with systemic chemotherapy.CONCLUSION: DEBIRITUX seems to be efficacious after first line chemotherapy for the treatment of unresectable CRC-LM. 相似文献